Drug

Anti-CD19 CAR T Cells AT101 clinical trials

studies test it: 14
open now: 1
in phase 3: 0
first study started: 2005

Keep track of what changes. Save the Anti-CD19 CAR T Cells AT101 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Combined with it in one product

AT-101: 10
Bcl-xL INHIBITOR: 1
R-(-)-gossypol acetic acid: 1
AT-101, prednisone and docetaxel: 1
AT-101 and docetaxel: 1
AT101(Anti-CD19 Chimeric Antigen Receptor T cell): 1
AT101: 1
Tarceva plus AT-101: 1

Studies by the year they started

14 studies that test it; most in 2006 (4)

Studies that test Anti-CD19 CAR T Cells AT101, by start year
Year	Studies
2005	2
2006	4
2007	3
2009	1
2010	2
2012	1
2022	1

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 2: 13

What it is tested for

Each study’s main condition, where its own words name it.

Prostatic Neoplasms: 4
Carcinoma, Non-Small-Cell Lung: 2
Laryngeal Neoplasms: 1
Lymphoma: 1
Lymphoma, Follicular: 1
Small Cell Lung Carcinoma: 1
Leukemia, Lymphocytic, Chronic, B-Cell: 1
Lymphoma, Non-Hodgkin: 1
Squamous Cell Carcinoma of Head and Neck: 1

Who runs them

Industry 10 · Other 4

Ascenta Therapeutics (9) · University of Michigan Rogel Cancer Center (2) · National Cancer Institute (NCI) (1) · AbClon (1) · University of Alabama at Birmingham (1)

Often tested with

Tested in the same studies.

Isosorbide (14) · Gossypol-acetic acid (14) · Gossypol acetic acid (14) · Docetaxel (2) · Prednisone (1) · Rituximab (1) · Topotecan (1) · Erlotinib (1)

Studies

Open first, then newest update. How each study uses Anti-CD19 CAR T Cells AT101 is read from its arms, and is right about nine times in ten.